辛伐他汀联合依折麦布在脑卒中合并血脂异常患者中的疗效及安全性观察

Safety and efficacy of simvastatin combined with ezetimibe in the treatment of stroke with dyslipidemia disease

目的研究辛伐他汀联合依折麦布在脑卒中合并血脂异常患者中的疗效及安全性。方法将114例脑卒中合并血脂异常患者随机分为辛伐他汀单药治疗组(57例)和辛伐他汀联合依折麦布治疗组(57例),比较2组患者的疗效、血脂水平变化情况及不良反应发生率。结果治疗24周后,联合治疗组的总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)显著低于单药治疗组(P<0.05),高密度脂蛋白(HDLC)显著高于单药治疗组(P<0.05)。2组患者不良反应发生率差异无统计学意义(P>0.05)。结论对于脑卒中合并血脂异常患者而言,辛伐他汀联合依折麦布具有较好的降脂效果,可以提高临床疗效,降低不良脑血管事件发生率,在对于他汀类药物不耐受的患者或单一他汀类药物治疗效果不佳时,联合依折麦布是一种安全有效的选择。

Objective To evaluate safety and efficacy of simvastatin combined with ezetimibe in the treatment of stroke with dyslipidemia disease.Methods 114 patients with stroke and dyslipidemia were randomly divided into simvastatin monotherapy group(57 cases)and simvastatin plus ezetimibe treatment group(57 cases).The study period was 24 weeks.Therapeutic efficacy,changes in blood lipid levels and incidence of adverse reactions.were compared between the two groups.Results After 24 weeks of treatment,total cholesterol(TC),triglyceride(TG),and low-density lipoprotein(LDL-C)in the combination group were significantly lower than those in the simvastatin monotherapy group(P<0.05),density lipoprotein(HDL-C)was significantly higher than simvastatin group(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with stroke and dyslipidemia,simvastatin combined with ezetimibe has a good lipid-lowering effect,which can improve the clinical efficacy and reduce the incidence of adverse cerebrovascular events.For patients with statin intolerance or a single statin treatment,combined ezetimibe is a safe and effective option.